Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Appraising the role of astrocytes as suppliers of neuronal glutathione precursors

  • Pérez-Sala, Dolores
  • Pajares, María Ángeles
The metabolism and intercellular transfer of glutathione or its precursors may play an important role in cellular defense against oxidative stress, a common hallmark of neurodegeneration. In the 1990s, several studies in the Neurobiology field led to the widely accepted notion that astrocytes produce large amounts of glutathione that serve to feed neurons with precursors for glutathione synthesis. This assumption has important implications for health and disease since a reduction in this supply from astrocytes could compromise the capacity of neurons to cope with oxidative stress. However, at first glance, this shuttling would imply a large energy expenditure to get to the same point in a nearby cell. Thus, are there additional underlying reasons for this expensive mechanism? Are neurons unable to import and/or synthesize the three non-essential amino acids that are the glutathione building blocks? The rather oxidizing extracellular environment favors the presence of cysteine (Cys) as cystine (Cis), less favorable for neuronal import. Therefore, it has also been proposed that astrocytic GSH efflux could induce a change in the redox status of the extracellular space nearby the neurons, locally lowering the Cis/Cys ratio. This astrocytic glutathione release would also increase their demand for precursors, stimulating Cis uptake, which these cells can import, further impacting the local decline of the Cis/Cys ratio, in turn, contributing to a more reduced extracellular environment and subsequently favoring neuronal Cys import. Here, we revisit the experimental evidence that led to the accepted hypothesis of astrocytes acting as suppliers of neuronal glutathione precursors, considering recent data from the Human Protein Atlas. In addition, we highlight some potential drawbacks of this hypothesis, mainly supported by heterogeneous cellular models. Finally, we outline additional and more cost-efficient possibilities by which astrocytes could support neuronal glutathione levels, including its shuttling in extracellular vesicles., This work was supported by “la Caixa” Foundation, Grant Agreement LCF/PR/HR21/52410002, the European Union Horizon H2020 EJP RD COFUND-EJP Nº 825575 “Alexander”, grants Nº RTI2018-097624-B-I00 and PID2021-126827OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to D.P.S., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia

  • Ficany, Anthony
  • Álamo, Marta del
  • Bernabeu, Carmelo
  • Shovlin, Claire L.
  • Rossi, Elisa
This article belongs to the Special Issue Hereditary Hemorrhagic Telangiectasia: Recent Advances and Future Challenges—2nd Edition., Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a vascular disorder with a global prevalence ranging from 1:5000 to 1:8000. It most commonly manifests through nosebleeds, which can be frequent and severe, exposing patients to major iron losses, anemia, and considerable physical and emotional distress. To date, no drug has received the FDA or EMA approval for preventing or treating HHT associated epistaxis, limiting access to therapies and intensifying the burden on patients and clinicians. Based on peer-reviewed evidence, the Second International HHT Guidelines provided a stepwise approach to help physicians manage HHT-related epistaxis highlighting the role of anti-fibrinolytic and systemic antiangiogenic drugs. However, experience from clinical practice and trials indicates marked variability in patient responses, and none of the recommended approaches has demonstrated sufficient placebo-controlled efficacy to gain regulatory approval. Striking insights in HHT physiopathology shed light on complex dysregulated signaling pathways with a triggering role not only by angiogenesis as widely recognized, but also by inflammation, injury and other stimuli, pointing to novel therapeutic targets. This review outlines current recommendations for preventing and managing nosebleeds in HHT patients, highlights the latest insights into the development of telangiectasic lesions, and discusses potential therapeutic treatments currently under clinical investigation., This research was funded by Université Paris Cité and AMRO Foundation [IDEX grant] to E.R., the European Union’s Horizon 2020 research and innovation program [EJP RD CO-FUND-EJP N° 825575] to M.D.A, and the NIHR Imperial Biomedical Research Centre (BRC) to C.L.S., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Reducing the global burden of cerebral venous thrombosis, An international research agenda

  • Coutinho, Jonathan M.
  • van de Munckhof, Anita|||0000-0001-6028-3426
  • Aguiar de Sousa, Diana|||0000-0002-6702-7924
  • Poli, Sven
  • Aaron, Sanjith|||0000-0002-5151-1500
  • Arauz, Antonio
  • Conforto, Adriana B.
  • Krzywicka, Katarzyna
  • Hiltunen, Sini
  • Lindgren, Erik
  • Sánchez van Kammen, Mayte
  • Shu, Liqi
  • Bakchoul, Tamam
  • Belder, Rosalie
  • van den Berg, René
  • Boumans, Elisheva
  • Cannegieter, Suzanne
  • Cano-Nigenda, Vanessa|||0000-0002-8544-9717
  • Field, Thalia S.|||0000-0002-1176-0633
  • Fragata, Isabel
  • Heldner, Mirjam R.
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Klok, Frederikus A.|||0000-0001-9961-0754
  • Leker, Ronen R.|||0000-0003-4794-0334
  • Lucas-Neto, L.
  • Molad, Jeremy|||0000-0001-6868-4849
  • Nguyen, Thanh N.|||0000-0002-2810-1685
  • Saaltink, Dirk-Jan
  • Saposnik, Gustavo|||0000-0002-5950-9886
  • Sharma, Pankaj
  • Stam, Jan
  • Thijs, Vincent|||0000-0002-6614-8417
  • van der Vaart, Michiel|||0000-0003-0828-7088
  • Werring, David J.|||0000-0003-2074-1861
  • Wong Ramos, Diana
  • Yaghi, Shadi
  • Yeşilot, Nilüfer|||0000-0002-9655-9487
  • Tatlisumak, Turgut
  • Putaala, Jukka|||0000-0002-6630-6104
  • Jood, Katarina|||0000-0001-8746-1771
  • Arnold, M.
  • Ferro, José M.|||0000-0002-2343-9097
Background: Due to the rarity of cerebral venous thrombosis (CVT), performing high-quality scientific research in this field is challenging. Providing answers to unresolved research questions will improve prevention, diagnosis, and treatment, and ultimately translate to a better outcome of patients with CVT. We present an international research agenda, in which the most important research questions in the field of CVT are prioritized. Aims: This research agenda has three distinct goals: (1) to provide inspiration and focus to research on CVT for the coming years, (2) to reinforce international collaboration, and (3) to facilitate the acquisition of research funding. Summary of review: This international research agenda is the result of a research summit organized by the International Cerebral Venous Thrombosis Consortium in Amsterdam, the Netherlands, in June 2023. The summit brought together 45 participants from 15 countries including clinical researchers from various disciplines, patients who previously suffered from CVT, and delegates from industry and non-profit funding organizations. The research agenda is categorized into six pre-specified themes: (1) epidemiology and clinical features, (2) life after CVT, (3) neuroimaging and diagnosis, (4) pathophysiology, (5) medical treatment, and (6) endovascular treatment. For each theme, we present two to four research questions, followed by a brief substantiation per question. The research questions were prioritized by the participants of the summit through consensus discussion. Conclusions: This international research agenda provides an overview of the most burning research questions on CVT. Answering these questions will advance our understanding and management of CVT, which will ultimately lead to improved outcomes for CVT patients worldwide.